PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (other OTC: “AVXT”) today announces it has expanded its ongoing Phase 1/2 study (“Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III or IV Ovarian Cancer”) to include all five Cancer Treatment Centers of America® (CTCA) regional hospitals. In addition, clinical data from the study was selected to be presented at the Society of Gynecologic Oncology (“SGO”) 19th Annual Winter Meeting February 20 – 22, 2014 at Breckenridge, Colorado. The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers.
“We are enthusiastic about continuing and expanding the clinical study with Cancer Treatment Centers of America,” stated Richard Rainey, Chief Executive Officer of AVAX. “We were honored to have our abstract selected for presentation at the SGO winter meeting and look forward to further communicating the interim trial results on the date of the presentation.”
Dr. David Berd, Chief Medical Officer of AVAX noted, “We are collaborating with CTCA to explore additional studies and protocols to offer additional treatment alternatives to their patients.”
“We are very excited to be part of a new chapter in the fight against ovarian cancer,” said Dr. Giuseppe Del Priore, National Director of Gynecologic Oncology at Cancer Treatment Centers of America. “Ovarian cancer is a very complex cancer that is often resistant to chemotherapy, radiation and surgery. At Cancer Treatment Centers of America, our commitment to cancer patients is to help fight their cancer with advanced medical technologies. This study works well with our unique care model, which combines rigorous, evidenced based state-of-the-art medicine with scientifically-based integrative therapies such as aggressive nutritional management, naturopathic medicine, physical therapy, and spiritual support, going beyond treating just the tumor to supporting the needs of the whole person.”
About the AC Vaccine Therapeutic
The AC Vaccine is an immunotherapy prepared by attaching a small chemical to the patient’s tumor cells in a process known as haptenization. This hapten modification allows the tumor cells to stimulate a T cell-based immune response to a patients own tumor cells. An early indicator of T cell immune activity is Delayed Type Hypersensitivity (DTH).
An understanding of what AVAX calls the immunopharmacology of the AC Vaccines is critical to their effective use. AVAX believes that the optimal dose, schedule of administration, and route of administration of human cancer vaccines must be established before they enter advanced phase studies, and that some competing vaccine technologies have failed because their developers ignored one or more of these parameters in early phase development.
About Ovarian Cancer
The American Cancer Society reports that ovarian cancer is the eighth most common cancer among women and is the fifth leading cause of cancer related deaths in women. It is estimated that there will be 22,240 new cases of ovarian caner in the U.S. in 2013 and 14,000 cancer related deaths.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. AVAX’s AC Vaccine platform is a therapeutic cancer vaccine. In addition, the Company performs contract-manufacturing services for biological products for other pharmaceutical and biotechnology companies.
Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the Company's prospects, including (1) risk associated with a change in executive management of the Company, (2) the immediate need to obtain additional funding to continue to finance the Company’s development plans, including the Phase I-II clinical trial for OVax described in this press release, (3) the results of clinical and laboratory testing of its vaccine technologies, (4) the Company's ability to maintain its rights under license agreements and to meet funding requirements under its license agreements, (5) the Company's ability to demonstrate the safety and efficacy of product candidates at each stage of development and to meet applicable regulatory standards and receive required regulatory approvals, as well as other risks detailed from time to time in AVAX's previous public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB. AVAX does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.